Indications |
Oral Depression Adult: Initially, 30-40 mg daily gradually increased if necessary. Maintenance: 30-90 mg daily as a single dose at night or in divided doses. Max: 200 mg/day. Elderly: Initially, 30 mg slowly increased if necessary. |
Contraindications |
lactation, porphyria. |
Warnings / Precautions |
Concurrent CNS depression; epilepsy; MAOIs withdrawal (at least 14 days after discontinuation); hepatic, renal or cardiac insufficiency; heart block or recent MI; angle-closure glaucoma; prostatic hyperplasia; diabetes mellitus; monitor blood count regularly. |
Adverse Reactions |
Drowsiness; liver dysfunction and jaundice; gynaecomastia; convulsions; hypomania; hypotension; hypertension; coma; arthralgia; oedema; tachycardia; bradycardia; vomiting; dizziness and ataxia; anticholinergic effects. Potentially Fatal: Bone marrow suppression. |
Overdose Reactions |
Symptoms are prolonged sedation, tachycardia and/or bradycardia. Treat with gastric lavage and supportive treatment. |
Drug Interactions |
Blood levels decreased by phenobarbitone, carbamazepine and phenytoin. Monitor blood pressure with antihypertensive therapy. Mianserin may antagonise the action of antiepileptics by lowering the convulsive threshold. CNS depressant effects enhance by alcohol, sedatives. Potentially Fatal: Avoid MAOIs (and for 14 days after discontinuation). See Below for More mianserin Drug Interactions |
Mechanism of Actions |
Mianserin is a structural analogue of serotonin (5-HT) with antagonistic effects at 5-HT2A, 5-HT2C and 5-HT3 receptors. Mianserin also blocks the inhibitory α2-receptors, thus leading to an increase in noradrenaline release. Absorption: Readily absorbed from the GIT (oral). Distribution: Widely distributed; crosses the blood-brain barrier; enters breast milk. Protein-binding: Extensive. Metabolism: Extensively hepatic by aromatic hydroxylation, N-oxidation, N-demethylation. Excretion: Urine (as metabolites), faeces (small amounts); 6-40 hrs (elimination half-life). |
Administration |
May be taken with or without food. |
ATC Classification |
N06AX03 - mianserin ; Belongs to the class of other antidepressants. |
Available As |
|
Mianserin
Post Review about Mianserin Click here to cancel reply.
Mianserin Containing Brands
Mianserin is used in following diseases
Drug - Drug Interactions of Mianserin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.